- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06411990
Laser In Situ Fenestration Study (LIFE)
May 13, 2024 updated by: Jonathan Bath
Laser In Situ Fenestration for Endovascular Aortic Repair (LIFE) Study
The goal of this clinical trial is to learn about a new device, named the LIFE device, to treat people with aneurysms (swellings) in the aorta (large, main blood vessel that delivers blood from the heart to the body). The main questions this trial aims to answer are:
- If the LIFE device works to treat aortic aneurysms
- What medical problems participants have when the LIFE device is used Participants will undergo treatment with the LIFE device and thereafter at 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years have their pulses checked, bloodwork to check kidney function (BUN and serum creatinine), and a CT scan of the aneurysm area.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
In this clinical trial the LIFE device is used to treat people with aneurysms in the aorta near the kidney arteries (called juxtarenal or pararenal aortic aneurysms).
Tubes, called stent grafts, are typically inserted through blood vessels in the groin and placed inside the aorta in the abdomen and chest area (endovascularly placed) to cover the tear or leak in the aorta.
The LIFE device covers the tear or leak and has side branches to let blood flow into the kidney, spleen, intestine, or liver arteries.
Participants in this study are not candidates for endovascular devices approved for endovascular aorta repair to the juxtarenal or pararenal aorta, not candidates for open repair, not willing to travel to sites that have access to manufacturer-made endovascular devices, and patients for whom there are no favorable alternatives, for example, urgent, symptomatic, and emergency cases.
Study Type
Interventional
Enrollment (Estimated)
15
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Nurse, Clinical Research
- Phone Number: 573-882-4387
- Email: randolphjl@health.missouri.edu
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Aortic aneurysm >5.5 cm in a man or > 5.0 cm in a woman or rapid expansion deemed at significant risk for rupture in the juxtarenal or pararenal aorta.
- Endovascular aortic repair requiring coverage of renovisceral branches.
- Not candidate or at high risk for open repair. For example, but not exclusively, due to renal dysfunction, previous abdominal surgery, obese body habitus, previous coronary bypass grafts or high cardiac risk, chronic obstructive pulmonary disease (COPD) or on oxygen at rest, poorly controlled diabetes, current smoking, or antiplatelet or anticoagulation use.
- Proximal aortic landing zone in Zone 5 of the aorta or previous graft of at least 10 mm in length and diameter of between 20 and 40 mm.
- Distance ≥ 5 mm between top of graft fabric and renovisceral branch orifice.
- At least a 5 mm iliofemoral artery to accept the endovascular stent graft device and an axillary brachial artery of sufficient diameter to accept the laser catheter.
- Renovisceral diameter between 4 and 13 mm at the origin.
- At the time of case planning, the patient's anatomy appears amenable to complete exclusion of the aneurysm with laser fenestration techniques.
- Not willing or able to travel to sites that have access to manufacturer-made investigational endovascular devices.
- Not a candidate for currently approved endovascular options.
- 18 years or older.
- Patient or legally authorized representative agrees to participate in the study and provides written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization.
- Patient is able and willing to meet all study requirements, including participating in follow up evaluations and attending required assessment visits.
Exclusion Criteria:
- Known sensitivities or allergies to the materials of construction of the devices, including Nitinol, polyester, Platinum-Iridium, stainless steel, fluoropolymer, and heparin.
- Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed.
- Uncorrectable coagulopathy.
- Body habitus that would inhibit radiographic visualization of the aorta or exceeds the safe capacity of equipment.
- Concurrent participation in another research protocol for investigation of an experimental therapy.
- Subject has been judged to be unsuitable for participation in the study by the Investigator for any reason.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Endovascular Aneurysm Repair
Fenestrated Endovascular Aneurysm Repair using the LIFE Device System
|
Fenestrated Endovascular Aneurysm Repair
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with freedom from death and major adverse events (MAE)
Time Frame: 30 days
|
Number of subjects with freedom from all cause mortality and freedom from major adverse events.
Major adverse events include myocardial infarction, chronic renal insufficiency / chronic renal failure requiring, dialysis, bowel ischemia, stroke, paraplegia or paraparesis, and prolonged ventilatory support.
|
30 days
|
Number of participants with device procedure technical success and freedom from endoleak, migration, aortic enlargement, aortic rupture, and aortic or branch-related reinterventions in
Time Frame: 12 months
|
Device technical success (at the end of index procedure) and freedom from Type I and III endoleak, device migration ≥ 10 mm, aortic enlargement ≥ 5 mm, aortic rupture, and aortic or branch-related reinterventions, including conversion to open repair (within 12 months of the index procedure)
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with delivery and deployment of the LIFE Device System
Time Frame: Procedure
|
Ability to deliver and deploy the LIFE Device System
|
Procedure
|
Number of participants with delivery and deployment of the thoracic/abdominal stent graft
Time Frame: Procedure
|
Ability to deliver and deploy the thoracic/abdominal stent graft
|
Procedure
|
Number of participants with coverage of intended aneurysm
Time Frame: Procedure
|
Ability to cover the intended aneurysm
|
Procedure
|
Number of participants with contrast flow into target renovisceral vessels
Time Frame: Procedure
|
Contrast flow into the target renovisceral vessels
|
Procedure
|
Estimated blood loss
Time Frame: Procedure
|
Estimated blood loss
|
Procedure
|
Ventilator days
Time Frame: From Procedure until the date of Hospital Discharge, typically 1-2 days
|
Ventilator days
|
From Procedure until the date of Hospital Discharge, typically 1-2 days
|
Days to oral intake
Time Frame: From Procedure until the date of Hospital Discharge, typically 1-2 days
|
Days to oral intake
|
From Procedure until the date of Hospital Discharge, typically 1-2 days
|
Intensive Care Unit (ICU) days
Time Frame: From Procedure until the date of Hospital Discharge, typically 1-2 days
|
ICU days recorded
|
From Procedure until the date of Hospital Discharge, typically 1-2 days
|
Days to hospital discharge
Time Frame: From Procedure until the date of Hospital Discharge, typically 1-2 days
|
Days to hospital discharge
|
From Procedure until the date of Hospital Discharge, typically 1-2 days
|
Procedure time
Time Frame: Procedure
|
Procedure time (minutes)
|
Procedure
|
Fluoroscopy time
Time Frame: Procedure
|
Fluoroscopy time (minutes)
|
Procedure
|
Endoleak rate
Time Frame: 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
|
Endoleak rate at 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
|
30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
|
Number of participants with device integrity failure
Time Frame: 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
|
Device integrity failure (e.g., fracture) at 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
|
30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
|
Number of participants with branch vessel device events
Time Frame: 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
|
Branch vessel device events (i.e., kink, stenosis, or occlusion at 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
|
30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
|
Number of participants with aortic growth
Time Frame: 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
|
Aortic growth - defined as an increase ≥ 5 mm in maximal aortic diameter in any segment at 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
|
30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
|
Number of participants with unplanned secondary procedures
Time Frame: 5 Years
|
Unplanned secondary procedures throughout follow-up (e.g., unanticipated aortic or branch-related reoperation)
|
5 Years
|
Number of participants with device migration
Time Frame: 6 Months, and 1, 2, 3, 4, and 5 Years
|
Device migration (radiographic), antegrade or retrograde movement of more than 10 mm relative to anatomic landmarks identified on the first (30 Day) post-operative CT scan, at 6 Months, and 1, 2, 3, 4, and 5 Years
|
6 Months, and 1, 2, 3, 4, and 5 Years
|
All adverse events
Time Frame: 5 Years
|
All adverse events throughout 5 year follow-up, including if MAE, serious adverse event (SAE) or unanticipated adverse device effect (UADE), and the relationship of the AE to the LIFE Procedure and LIFE Device System
|
5 Years
|
Freedom from aneurysm-related mortality
Time Frame: 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
|
Freedom from aneurysm-related mortality at 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
|
30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
|
Freedom from all-cause mortality
Time Frame: 6 Months and 1, 2, 3, 4, and 5 Years
|
Freedom from all-cause mortality at 6 Months and 1, 2, 3, 4, and 5 Years
|
6 Months and 1, 2, 3, 4, and 5 Years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jonathan Bath, MD, University of Missouri School - Columbia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2024
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
June 1, 2031
Study Registration Dates
First Submitted
April 30, 2024
First Submitted That Met QC Criteria
May 10, 2024
First Posted (Actual)
May 14, 2024
Study Record Updates
Last Update Posted (Actual)
May 16, 2024
Last Update Submitted That Met QC Criteria
May 13, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2102631
- 2023-001 (Other Identifier: University of Missouri)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Aneurysm
-
University of BolognaCompletedThoracoabdominal Aortic Aneurysm | Ruptured Thoracic Aneurysm | Ruptured Aortic Aneurysm | Thoracoabdominal Aortic Aneurysm, RupturedItaly
-
Gustavo OderichWilliam Cook AustraliaRecruitingThoracoabdominal Aortic Aneurysm | Aortic Arch Aneurysm | Complex Abdominal Aortic Aneurysm | Aortic Arch DissectionUnited States
-
Baptist Health South FloridaWilliam Cook AustraliaRecruitingThoracoabdominal Aortic Aneurysm | Aortic Arch AneurysmUnited States
-
University of California, San DiegoRecruitingJuxtarenal Aortic Aneurysm | Thoracoabdominal Aortic Aneurysm | Pararenal Aortic Aneurysm | Complex Abdominal Aortic AneurysmUnited States
-
University of South FloridaMedtronic; Sanford HealthActive, not recruiting
-
University of North Carolina, Chapel HillCook Group Incorporated; UNC HospitalsEnrolling by invitationAortic Aneurysm, Abdominal | Aortic Arch Aneurysm | Ascending Aorta AneurysmUnited States
-
Karolinska University HospitalEnrolling by invitationAneurysm | Aortic Aneurysm | Abdominal Aortic Aneurysm, Ruptured | Aneurysm Abdominal | Abdominal Aortic Aneurysm Without RuptureSweden
-
Rede Optimus Hospitalar SAShockwave Medical, Inc.Not yet recruitingThoracoabdominal Aortic Aneurysm, Without Mention of Rupture | Abdominal Aortic Aneurysm Without Rupture | Thoracic Aortic Aneurysm Without Rupture
-
CEVARIIUniversity of Colorado, Denver; University of Copenhagen; University of Iowa; University... and other collaboratorsEnrolling by invitationComplex EVAR in Inflammatory and Infective Abdominal and Thoracoabdominal Aortic Aneurysms (CEVARII)Abdominal Aortic Aneurysm | Thoracoabdominal Aortic Aneurysm | Aneurysm, Infected | Inflammatory Abdominal Aortic Aneurysm | Aneurysm, MycoticUnited States
-
W.L.Gore & AssociatesRecruitingThoracic Aortic Aneurysm | Abdominal Aortic AneurysmSpain, Denmark, Italy, Norway, Netherlands, Sweden
Clinical Trials on Fenestrated Endovascular Aneurysm Repair using the LIFE Device System
-
Tara MastracciUniversity Hospital, Lille; Skane University HospitalNot yet recruitingAneurysm | Aortic Aneurysm
-
EndologixCompletedAbdominal Aortic AneurysmUnited States, New Zealand, Chile, France, Netherlands, United Kingdom
-
Rijnstate HospitalMedtronicRecruitingAortic Aneurysm, AbdominalUnited States, Netherlands, France
-
University of North Carolina, Chapel HillCook Group Incorporated; UNC HospitalsEnrolling by invitationAortic Aneurysm, Abdominal | Aortic Arch Aneurysm | Ascending Aorta AneurysmUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedComplex Abdominal Aortic Aneurysm, ie. Juxtarenal or Suprarenal Aortic Aneurysms, Treated by Fenestrated Endovascular Aortic Aneurysm Repair or Open RepairFrance
-
Stanford UniversityCompleted
-
Rijnstate HospitalWithdrawnInflammatory Response | Abdominal Aortic AneurysmNew Zealand, Netherlands, Spain, Germany, Poland
-
Medtronic CardiovascularTerminated
-
Medtronic CardiovascularTerminatedAbdominal Aortic Aneurysm | AAANetherlands, Belgium, Denmark, Sweden, Austria
-
EndologixCompletedAbdominal Aortic AneurysmsNew Zealand, Colombia, Latvia, Venezuela